        item: #1 of 39
          id: cord-000079-533xlisc
      author: Huszthy, Peter C.
       title: Remission of Invasive, Cancer Stem-Like Glioblastoma Xenografts Using Lentiviral Vector-Mediated Suicide Gene Therapy
        date: 2009-07-20
       words: 5455
      flesch: 41
     summary: One major drawback of gammaretroviral vectors is the exclusive transduction of dividing cells, since in human gliomas, the majority of tumor cells do not divide within a given treatment window. LCMV-GP pseudotyped lentiviral vectors exclusively transduced tumor cells in all invasive areas ( Figure 4A ), while normal brain cells were not transduced ( Figure 4B,C) .
    keywords: brain; cells; figure; gene; glioblastoma; glioma; lcmv; lentiviral; spheroids; stem; tumor; vectors; vsv
       cache: cord-000079-533xlisc.txt
  plain text: cord-000079-533xlisc.txt

        item: #2 of 39
          id: cord-000660-tsvzg0ax
      author: Fensterl, Volker
       title: Interferon-Induced Ifit2/ISG54 Protects Mice from Lethal VSV Neuropathogenesis
        date: 2012-05-17
       words: 8309
      flesch: 48
     summary: In wt mice, VSV RNA was present prominently in the cortex, midbrain and brainstem, but not in the cerebellum ( Figure 4C ), which is consistent with published results [24] . Ifit1 and IFN-b mRNAs were induced as strongly in OB of Ifit22/2 as in wt mice, which correlated well with similar abundance of VSV RNA in wt and Ifit2 2/2 OB (Figure 5A compared to Figure 3C ).
    keywords: 2/2; brain; d.p.i; figure; ifit2; ifn; infection; mice; protein; replication; rna; type; virus; vsv; wt mice
       cache: cord-000660-tsvzg0ax.txt
  plain text: cord-000660-tsvzg0ax.txt

        item: #3 of 39
          id: cord-001765-7wv4cb37
      author: Matassov, Demetrius
       title: Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus
        date: 2015-06-24
       words: 4876
      flesch: 41
     summary: Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus Fruit bats as reservoirs of Ebola virus Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species Ebola-a growing threat? Case fatality rate for Ebola virus disease in West Africa Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection Progress in filovirus vaccine development: evaluating the potential for clinical use Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus Recombinant vesicular stomatitis virusbased vaccines against Ebola and Marburg virus infections The epizootiology of the vesicular stomatitis viruses: a reappraisal Vesicular stomatitis virus, Indiana serotype: multiplication in and transmission by experimentally infected phlebotomine sandflies (Lutzomyia trapidoi) Vesicular stomatitis virus (Indiana serotype): transovarial transmission by phlebotomine sandflies Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV) Natural infection of humans, animals, and phlebotomine sand flies with the Alagoas serotype of vesicular stomatitis virus in Colombia Recombinant vesicular stomatitis viruses from DNA Replicationcompetent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine Attenuated vesicular stomatitis viruses as vaccine vectors An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants Sequential transcription of the genes of vesicular stomatitis virus Order of transcription of genes of vesicular stomatitis virus Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates Attenuation of recombinant vesicular stomatitis virus HIV-1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations Guide for the care and use of laboratory animals An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development A simple method of estimating fifty percent endpoints Pathogenesis of experimental Ebola virus infection in guinea pigs Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis Ebola virus-like particles protect from lethal Ebola virus infection Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors Natural killer cells in antiviral defense: function and regulation by innate cytokines Financial support.
    keywords: challenge; ebola; ebovgp; gene; guinea; mice; n4ct1; rvsv; stomatitis; vaccine; vector; virus
       cache: cord-001765-7wv4cb37.txt
  plain text: cord-001765-7wv4cb37.txt

        item: #4 of 39
          id: cord-003667-u1xa44nw
      author: Rodriguez, Sergio E.
       title: Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever
        date: 2019-05-23
       words: 8093
      flesch: 40
     summary: The role of ticks in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus: A review of published field and laboratory studies Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity Crimean-Congo haemorrhagic fever Crimean-Congo hemorrhagic fever virus: New outbreaks, new discoveries Treatment of Crimean-Congo hemorrhagic fever Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus Crimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus Cellular Localization and Antigenic Characterization of Crimean-Congo Hemorrhagic Fever Virus Glycoproteins Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus Development of vaccines against Crimean-Congo haemorrhagic fever virus Crimean-Congo hemorrhagic fever virus infection is lethal for adult type Several CCHFV experimental vaccines studies have identified cell-mediated and humoral involvement, with some instances of neutralizing antibody production 24, 57 .
    keywords: cchfv; cells; challenge; congo; crimean; fever; fig; gpc; gpcδ; group; mice; mouse; prime; protein; replication; stomatitis; study; vaccine; vector; virus; vsv; δgrvsv
       cache: cord-003667-u1xa44nw.txt
  plain text: cord-003667-u1xa44nw.txt

        item: #5 of 39
          id: cord-004126-u6ts87ur
      author: Furuyama, Wakako
       title: A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades
        date: 2020-01-10
       words: 6045
      flesch: 44
     summary: Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO Novel Eurasian highly pathogenic avian influenza A H5 viruses in wild birds Novel reassortant influenza A(H5N8) viruses among inoculated domestic and wild ducks Intercontinental spread of Asian-origin H5N8 to North America through Beringia by migratory birds Reassortant highly pathogenic influenza A H5N2 virus containing gene segments related to Eurasian H5N8 in British Columbia Novel reassortant highly pathogenic H5N6 avian influenza viruses in poultry in China Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China Avian flu: isolation of drug-resistant H5N1 virus Lethal H5N1 influenza viruses escape host anti-viral cytokine responses Scientific barriers to developing vaccines against avian influenza viruses Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture Emerging vaccines for influenza Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants A VSV-based Zika virus vaccine protects mice from lethal challenge Single-dose liveattenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials Ebola: lessons on vaccine development Keeping your cool -doing Ebola research during an emergency Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection Characterization of a bivalent vaccine capable of inducing protection against both Ebola and cross-clade H5N1 influenza in mice Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1 Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: abridged chronology and virus isolation H5N1 highly pathogenic avian influenza: timeline of major events Brief literature review for the WHO global influenza research agenda-highly pathogenic avian influenza H5N1 risk in humans Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1) Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness Haemagglutination-inhibiting antibody to influenza virus Cross-clade immunity in cats vaccinated with a canarypoxvectored avian influenza vaccine Towards a universal influenza vaccine: different approaches for one goal Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates Ebola haemorrhagic fever VSVDeltaG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection Cell culture-based influenza vaccines: a necessary and indispensable investment for the future Ebola vaccines in clinical trial: the promising candidates Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses We thank the animal care staff of the Rocky Mountain Veterinary Branch (NIAID, NIH) for their support of the animal experiments. Next, we performed a series of studies measuring the rate and extent of vaccine virus growth over time.
    keywords: challenge; ebov; fig; h5n1; hafl; influenza; mice; shazip; supplementary; vaccine; vectors; virus; viruses; vsv
       cache: cord-004126-u6ts87ur.txt
  plain text: cord-004126-u6ts87ur.txt

        item: #6 of 39
          id: cord-004733-i0a3igc7
      author: Nagata, S.
       title: Identification of epitopes associated with different biological activities on the glycoprotein of vesicular stomatitis virus by use of monoclonal antibodies
        date: 1992
       words: 5170
      flesch: 49
     summary: key: cord-004733-i0a3igc7 authors: Nagata, S.; Okamoto, Y.; Inoue, T.; Ueno, Y.; Kurata, T.; Chiba, J. title: Identification of epitopes associated with different biological activities on the glycoprotein of vesicular stomatitis virus by use of monoclonal antibodies date: 1992 journal: Arch Virol DOI: 10.1007/bf01309581 sha: doc_id: 4733 cord_uid: i0a3igc7 Thirteen monoclonal antibodies (MAbs) to the glycoprotein (G) of vesicular stomatitis virus (VSV) serotype Indiana were prepared and examined for their effects on various biological activities of VSV, including in vitro infection, hemagglutination, adsorption to cells, and mediation of cell fusion. Monoclonal antibodies to nonneutralizing and cross-reactive epitope of Indiana and New Jersey serotypes Antigenic determinants of vesicular stomatitis virus: analysis with antigenic variants Point mutations in glycoprotein gene of vesicular stomatitis virus (New Jersey serotype) selected by resistance to neutralization by epitope-specific monoclonal antibodies Spontaneous mutations leading to antigenic variations in the glycoproteins of vesicular stomatitis virus field isolates pH-dependent hemolysis and cell fusion of rhabdoviruses Virus entry into animal cells Pathway of vesicular stomatitis virus entry leading to infection Transepithelial transport of a viral membrane glycoprotein implanted into the apical plasma membrane of Madin-Darby canine kidney cells.
    keywords: binding; cells; epitopes; fusion; mabs; protein; stomatitis; virus; vsv
       cache: cord-004733-i0a3igc7.txt
  plain text: cord-004733-i0a3igc7.txt

        item: #7 of 39
          id: cord-008556-oetrdm8g
      author: Kozak, Marilyn
       title: Regulation of Protein Synthesis in Virus-Infected Animal Cells
        date: 2008-03-01
       words: 23992
      flesch: 40
     summary: On the regulation of protein synthesis in vaccinia virus infected cells A joint product of the genes gag and pol of avian sarcoma virus: A possible precursor of reverse transcriptase Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells The influence of the host cell on the inhibition of virus protein synthesis in cells doubly infected with VSV and mengovirus Sequence studies of several alphavirus genomic RNAs in the region containing the start of the subgenomic RNA Characterization of a ts mutant of vaccinia virus 25,422-426. The replication of picornaviruses Expression from an internal AUG codon of herpes simplex thymidine kinase gene inserted in a retrovirus vector The number of ribosomes on SV40 late 16s mRNA is determined in part by the nucleotide sequence of its leader Complete nucleotide sequence of alfalfa mosaic virus RNA 3 Sequence analysis of hepatitis A virus cDNA coding for capsid proteins and RNA polymerase Direct mapping of adeno-associated virus capsid proteins B and C: A possible ACG initiation codon Structure of the FMDV translation initiation site and of the structural proteins UAG readthrough during TMV RNA translation: Isolation and sequence of two tRNAsTyr with suppressor activity from tobacco plants The molecular basis for differential translation of TMV RNA in tobacco and wheat germ Measles virus P gene codes for two proteins Inhibition of HeLa cell protein synthesis during adenovirus infection Regulatory mutants of polyoma virus defective in DNA replication and the synthesis of early proteins Solubilization of a protein synthesis inhibitor from vaccinia virions Codon selection in yeast Translational interference a t overlapping reading frames in prokaryotic mRNA Effect of the tripartite leader on synthesis of a nonviral protein in an adenovirus 5 recombinant Poliovirus mutant that does not selectively inhibit host cell protein synthesis Two small RNAs encoded by Epstein-Barr virus can functionally substitute for the virus-associated RNAs in the lytic growth of adenovirus 5 Construction and analysis of additional adenovirus substitution mutants confirm the complementation of VAI RNA function by two small RNAs encoded by Epstein-Barr virus Structural requirements of adenovirus VAI RNA for its translation enhancement function Differential inhibition of host cell RNA synthesis in several picornavirus-infected cell lines Effect of viral infection on host protein synthesis and mRNA association with the cytoplasmic cytoskeletal structure Intermolecular duplexes formed from polyadenylated vaccinia virus RNA
    keywords: adenovirus; aug; binding; cap; cells; codon; et al; gene; host; host mrnas; host protein; host translation; infection; influenza; inhibition; initiation; late; mechanism; mrnas; poliovirus; protein; protein synthesis; reovirus; ribosomes; sequence; shutoff; site; synthesis; translation; upstream; vaccinia; viral; virus; virus mrnas
       cache: cord-008556-oetrdm8g.txt
  plain text: cord-008556-oetrdm8g.txt

        item: #8 of 39
          id: cord-011435-x73foqu7
      author: Glanz, Anna
       title: High Throughput Screening of FDA-Approved Drug Library Reveals the Compounds that Promote IRF3-Mediated Pro-Apoptotic Pathway Inhibit Virus Replication
        date: 2020-04-14
       words: 8452
      flesch: 36
     summary: Therefore, in contrast to doxorubicin, which differentially modulates IRF3 activity by promoting RIPA and inhibiting the IRF3 transcriptional branch, PP exclusively promotes RIPA without affecting IRF3 transcriptional activity. Therefore, in contrast to doxorubicin, which differentially modulates IRF3 activity by promoting RIPA and inhibiting the IRF3 transcriptional branch, PP exclusively promotes RIPA without affecting IRF3 transcriptional activity.
    keywords: activity; cells; doxorubicin; figure; inhibited; irf3; pathway; replication; results; ripa; rlr; transcriptional; virus; vsv
       cache: cord-011435-x73foqu7.txt
  plain text: cord-011435-x73foqu7.txt

        item: #9 of 39
          id: cord-020714-h1fevqcw
      author: Compans, Richard W.
       title: Membrane Glycoproteins of Enveloped Viruses
        date: 2008-05-30
       words: 14170
      flesch: 35
     summary: The carbohydrate content and glycoproteins of the virion An electron microscope study of the presence or absence of neuraminic acid in enveloped viruses On the structure of the influenza virus envelope Inhibition of glycoprotein biosynthesis of influenza virus by D-glucosamine and 2-deoxy-~-glucose Association of influenza virus proteins with cytoplasmic fractions Activation of influenza A viruses by trypsin treatment A sedimentable component of allantoic fluid and.its relationship to influenza viruses Separate pathways of maturation ofthe major structural proteins of vesicular stomatitis virus Subsequent biochemical studies revealed that high concentrations of 2-dG or Dglucosamine prevented the synthesis of influenza virus glycoproteins (Klenk et al., 1972b Nakamura and Compans, 1978a) .
    keywords: acid; bilayer; cell; components; envelope; et al; glycoproteins; host; influenza; influenza virus; lipid; membrane; structure; studies; surface; type; virions; virus; viruses
       cache: cord-020714-h1fevqcw.txt
  plain text: cord-020714-h1fevqcw.txt

        item: #10 of 39
          id: cord-104239-xxlcdbqi
      author: None
       title: The organization of endoplasmic reticulum export complexes
        date: 1996-10-01
       words: 11318
      flesch: 45
     summary: We find that ER buds in vivo are nonrandomly distributed, being concentrated in regional foci we refer to as export complexes. We find that ER buds in vivo are nonrandomly distributed, being concentrated in regional foci we refer to as export complexes.
    keywords: budding; buds; cells; et al; export; fig; golgi; membrane; number; sections; surface; vesicles; vsv; vtcs
       cache: cord-104239-xxlcdbqi.txt
  plain text: cord-104239-xxlcdbqi.txt

        item: #11 of 39
          id: cord-262752-bwofzbwa
      author: Li, Qianqian
       title: Current status on the development of pseudoviruses for enveloped viruses
        date: 2017-12-07
       words: 3282
      flesch: 22
     summary: Pseudotype formation between enveloped RNA and DNA viruses Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines Quantification of lyssavirus-neutralizing antibodies using vesicular stomatitis virus pseudotype particles Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase A system for functional analysis of Ebola virus glycoprotein Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors Characterization of pseudotype VSV possessing HCV envelope proteins Use of vesicular stomatitis virus pseudotypes bearing Hantaan or Seoul virus envelope proteins in a rapid and safe neutralization test A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice Study of Andes virus entry and neutralization using a pseudovirion system Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies Analyses of entry mechanisms of novel emerging viruses using pseudotype VSV system Characterization of the interaction of Lassa fever virus with its cellular receptor alpha-dystroglycan Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus Development of a neutralization assay for Nipah virus using pseudotype particles EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein Involvement of ceramide in the propagation of Japanese encephalitis virus Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein Efficient generation of vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines R-E- The VSV packaging system is a versatile tool for making pseudotyped viruses; this system is advantageous in that it has no stringent selectivity for the envelope proteins, and the resulting virus may be manipulated in a BSL-2 laboratory.
    keywords: envelope; neutralization; packaging; plasmid; pseudovirus; system; virus; viruses; vsv
       cache: cord-262752-bwofzbwa.txt
  plain text: cord-262752-bwofzbwa.txt

        item: #12 of 39
          id: cord-262753-jld1ygxt
      author: Neidermyer, William J.
       title: Global analysis of polysome-associated mRNA in vesicular stomatitis virus infected cells
        date: 2019-06-21
       words: 9262
      flesch: 40
     summary: Collectively, these studies suggest additional mechanisms may contribute to the shut-off of host cell protein synthesis. An RNA polymerase in the virion L protein requirement for in vitro RNA synthesis by vesicular stomatitis virus Transcriptional activity and mutational analysis of recombinant vesicular stomatitis virus RNA polymerase Amino acid residues within conserved domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA cap methyltransferase activity A single amino acid change in the L-polymerase protein of vesicular stomatitis virus completely abolishes viral mRNA cap methylation A unique strategy for mRNA cap methylation used by vesicular stomatitis virus Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus A conserved motif in region v of the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping Rebinding of transcriptase components (L and NS proteins) to the nucleocapsid template of vesicular stomatitis virus Location of the binding domains for the RNA polymerase L and the ribonucleocapsid template within different halves of the NS phosphoprotein of vesicular stomatitis virus Structure of the vesicular stomatitis virus nucleoprotein-RNA complex Structure of the vesicular stomatitis virus nucleocapsid in complex with the nucleocapsid-binding domain of the small polymerase cofactor Molecular architecture of the vesicular stomatitis virus RNA polymerase Critical phosphoprotein elements that regulate polymerase architecture and function in vesicular stomatitis virus Synthesis of poly(A) in vitro by purified virions of vesicular stomatitis virus In vitro synthesis of RNA that contains polyadenylate by virion-associated RNA polymerase of vesicular stomatitis virus Site on the vesicular stomatitis virus genome specifying polyadenylation and the end of the L gene mRNA Aberrant polyadenylation by a vesicular stomatitis virus mutant is due to an altered L protein cis-Acting signals involved in termination of vesicular stomatitis virus mRNA synthesis include the conserved AUAC and the U7 signal for polyadenylation Translational control of protein synthesis after infection by vesicular stomatitis virus Vesicular stomatitis virus mRNA and inhibition of translation of cellular mRNA-is there a P function in vesicular stomatitis virus? Effect of intracellular vesicular stomatitis virus mRNA concentration on the inhibition of host cell protein synthesis Complete intergenic and flanking gene sequences from the genome of vesicular stomatitis virus Complete sequences of the ribosome recognition sites in vesicular stomatitis virus
    keywords: associated; association; cells; cellular; eif4e; fig; gene; host; hpi; infection; mrnas; polysome; protein; reads; stomatitis; synthesis; translation; virus; vsv
       cache: cord-262753-jld1ygxt.txt
  plain text: cord-262753-jld1ygxt.txt

        item: #13 of 39
          id: cord-267712-mhx8e5y0
      author: Fang, Xinkui
       title: Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors
        date: 2012-02-08
       words: 5838
      flesch: 51
     summary: In short, confluent BHK21 cells were infected with VSV M51, VSV G 28 or VSV M51-G 28 at a multiplicity of infection (MOI) of 1. In VSV M51 infected cells, IFN-␤ concentrations reached ∼2000 pg/mL, but the highest replication titer was ∼2 orders of magnitude lower than for VSV XN2 .
    keywords: animals; cells; m51; mice; protein; virus; vsv; vsv m51; xn2
       cache: cord-267712-mhx8e5y0.txt
  plain text: cord-267712-mhx8e5y0.txt

        item: #14 of 39
          id: cord-268565-2sg1tlrg
      author: Clarke, David K.
       title: Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector
        date: 2006-09-15
       words: 8297
      flesch: 28
     summary: Sequential transcription of the genes of vesicular stomatitis virus Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis Role of the nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis Order of transcription of genes of vesicular stomatitis virus Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus Multiplication in and transmission by Aedes aegypti of vesicular stomatitis virus Chandipura: a new Arbovirus isolated in India from patients with febrile illness Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo Interaction of VSV leader RNA and nucleocapsid protein may control VSV genome replication N protein of vesicular stomatitis virus selectively encapsidates leader RNA in vitro Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins A newly recognized vesiculovirus, Calchaqui virus, and subtypes of Melao and Maguari viruses from Argentina, with serologic evidence for infections of humans and horses Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene The matrix (M) protein of vesicular stomatitis virus regulates transcription Basic amino acid residues at the carboxy-terminal eleven amino acid region of the phosphoprotein (P) are required for transcription but not for replication of vesicular stomatitis virus genome RNA Isolation of Chandipura virus from sandflies in Aurangabad RNA virus mutations and fitness for survival Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway Human infection with the virus of vesicular stomatitis during an epizootic Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals Monkey neurovirulence test for live mumps vaccine The budding mechanism of spikeless vesicular stomatitis virus particles Neuropathological and immunofluorescence studies of experimental vesicular stomatitis virus encephalitis in mice Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge Comparative studies on the viruses of vesicular stomatitis and equine encephalomyelitis Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication Cell-free synthesis and assembly of vesicular stomatitis virus nucleocapsids The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system Genetic characteristics of conditional lethal mutants of vesicular stomatitis virus induced by 5-fluorouracil, 5-azacytidine, and ethyl methane sulfonate The genetics of vesiculoviruses Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals Experimental transmission of Chandipura virus by mosquitoes Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease Cell surface expression of fusogenic vesicular stomatitis virus G protein from cloned cDNA Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge Attenuated vesicular stomatitis viruses as vaccine vectors The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly Rhabdoviridae: the viruses and their replication Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1 An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants Neurological manifestations of avian influenza viruses in mammals The mumps virus neurovirulence safety test in rhesus monkeys: a comparison of mumps virus strains Influence of host factors on neuroinvasiveness of vesicular stomatitis virus: C. C. Thomas Growth and transovarial transmission of Chandipura virus (Rhabdoviridae: Vesiculovirus) in Phlebotomus papatasi Ecologic studies of vesicular stomatitis virus.
    keywords: attenuation; cell; expression; gene; genome; protein; replication; responses; rna; rvsv; stomatitis; transcription; vaccine; vectors; virus
       cache: cord-268565-2sg1tlrg.txt
  plain text: cord-268565-2sg1tlrg.txt

        item: #15 of 39
          id: cord-270380-1me7ugkg
      author: Wang, Xiaona
       title: Cloning, Prokaryotic Soluble Expression, and Analysis of Antiviral Activity of Two Novel Feline IFN-ω Proteins
        date: 2020-03-19
       words: 5965
      flesch: 36
     summary: Furthermore, the antiviral activity of rfeIFN-ωb was better than that of rfeIFN-ωa in homologous and heterologous animal cells, but especially in homologous animal cells that originated from cats. Furthermore, the antiviral activity of rfeIFN-ωb was better than that of rfeIFN-ωa in homologous and heterologous animal cells, but especially in homologous animal cells that originated from cats.
    keywords: activity; antiviral; cells; feline; figure; intercat; proteins; rfeifn; vsv
       cache: cord-270380-1me7ugkg.txt
  plain text: cord-270380-1me7ugkg.txt

        item: #16 of 39
          id: cord-272051-arz8r204
      author: Federico, Maurizio
       title: HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step
        date: 2011-08-15
       words: 6787
      flesch: 45
     summary: However, it is now accepted that this family of inhibitors can also affect the activity of cell proteases. The concept that the activity of cell proteases is part of the mechanisms underlying the replication of many virus species is widely accepted.
    keywords: cells; effect; fusion; hiv-1; influenza; pis; protease; replication; virus; vsv
       cache: cord-272051-arz8r204.txt
  plain text: cord-272051-arz8r204.txt

        item: #17 of 39
          id: cord-275348-jna496x7
      author: Kapadia, Sagar U.
       title: SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector
        date: 2008-06-20
       words: 5987
      flesch: 45
     summary: VSV G protein is the target of VSV neutralizing antibodies (Kelley et al., 1972) . VSVΔG-EGFP1 pseudotyped with either SΔtail-HA or VSV G proteins were incubated with antiserum from mice immunized with wt VSV, VSV-S or SARS-CoV as indicated.
    keywords: cells; cov; infection; mice; protein; sars; virus; vsv; vsvδg
       cache: cord-275348-jna496x7.txt
  plain text: cord-275348-jna496x7.txt

        item: #18 of 39
          id: cord-276009-p98wjtjb
      author: Iyer, Arun V.
       title: Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01
        date: 2009-02-05
       words: 7553
      flesch: 39
     summary: A neurotropic virus isolated from the blood of a native of Uganda Flaviviridae: the viruses and their replication Structures of immature flavivirus particles Conformational changes of the flavivirus E glycoprotein Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States Possible West Nile virus transmission to an infant through breast-feeding-Michigan West Nile virus infection: a pediatric perspective Transfusion-associated transmission of West Nile virus-Arizona Investigations of West Nile virus infections in recipients of blood transfusions Detection of West Nile virus in blood donations-United States A fatal case of West Nile virus infection in a bone marrow transplant recipient Nile virus infection in organ donor and transplant recipients-Georgia and Florida Transmission of West Nile virus from an organ donor to four transplant recipients Possible dialysis-related west nile virus transmission-Georgia The West Nile Virus and the dialysis/transplant patient West Nile virus: pathogenesis and therapeutic options Skin manifestations of West Nile virus infection Characteristics of the rash associated with West Nile virus fever West Nile virus neuroinvasive disease West Nile virus infection: a new acute paralytic illness West Nile encephalitis presenting as a stroke Acute pancreatitis in West Nile fever The pathology of human West Nile virus infection West Nile virus encephalitis with myositis and orchitis West Nile virus (WNV) was first isolated more than 70 years ago from a febrile patient in the West Nile province of Uganda [1] .
    keywords: animals; cells; challenge; glycoprotein; immune; mice; nile; recombinant; responses; stomatitis; vaccine; vesicular; virus; vsv; west; wnv
       cache: cord-276009-p98wjtjb.txt
  plain text: cord-276009-p98wjtjb.txt

        item: #19 of 39
          id: cord-277823-vijh6x1l
      author: TERAMICHI, Takurou
       title: Evaluation of serological assays available in a biosafety level 2 laboratory and their application for survey of Middle East respiratory syndrome coronavirus among livestock in Ethiopia
        date: 2019-11-05
       words: 2260
      flesch: 45
     summary: In dromedary camels and cattle, 31 out of 38 and 1 out of 15, respectively, were MERS antibody positive. Goats and sheep were all MERS antibody negative (Table l) .
    keywords: antibody; cov; gfp; mers; neutralization; vsv
       cache: cord-277823-vijh6x1l.txt
  plain text: cord-277823-vijh6x1l.txt

        item: #20 of 39
          id: cord-285749-0ejhd9nw
      author: Hoffmann, Markus
       title: The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells
        date: 2016-03-30
       words: 6052
      flesch: 41
     summary: BatFLUAV-HAL does not use sialic acids for host cell entry FLUAV employ alpha-2,3-(avian viruses) and alpha-2,6-linked (human viruses) sialic acids as receptors for host cell entry [47] Finally, the type II transmembrane serine protease TMPRSS2 was able to activate HAL for cell entry indicating that batFLUAV can utilize human proteases for HAL activation.
    keywords: batfluav; cells; entry; hal; human; influenza; proteins; pseudotypes; tmprss2; trypsin; virus; viruses
       cache: cord-285749-0ejhd9nw.txt
  plain text: cord-285749-0ejhd9nw.txt

        item: #21 of 39
          id: cord-286390-ytgw3j4s
      author: Case, James Brett
       title: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
        date: 2020-07-03
       words: 1674
      flesch: 11
     summary: Lassa virus entry requires a 676 trigger-induced receptor switch Live attenuated recombinant vaccine 680 protects nonhuman primates against Ebola and Marburg viruses Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute 684 respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells Therapeutic strategies in an outbreak scenario to treat the novel coronavirus 687 originating in Wuhan, China CoV-2 spike pseudotyped virus by recombinant ACE2-Ig Functional assessment of cell entry and receptor 693 usage for SARS-CoV-2 and other lineage B betacoronaviruses Structure of SARS coronavirus spike 696 receptor-binding domain complexed with receptor The Sequence Alignment/Map format and SAMtools A unique strategy for mRNA cap methylation used 703 by vesicular stomatitis virus Angiotensin-converting enzyme 2 is 707 a functional receptor for the SARS coronavirus Intracellular targeting signals contribute to 710 localization of coronavirus spike proteins near the virus assembly site The cytoplasmic tail of the severe acute 713 respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval 714 signal that binds COPI and promotes interaction with membrane protein Synthetic antibodies neutralize SARS-CoV-2 718 infection of mammalian cells Retroviruses pseudotyped with the severe acute respiratory 722 syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting 723 enzyme 2 Enhancing dengue virus maturation using a stable furin over-expressing cell line Establishment and validation of a pseudovirus neutralization assay for Emerging microbes & infections 9 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-735 reactivity with SARS-CoV Cross-neutralization of SARS-CoV-2 by a human 742 monoclonal SARS-CoV antibody Dipeptidyl peptidase 4 is a functional receptor for the 746 emerging human coronavirus-EMC The coronavirus E protein: assembly and beyond. 749 Viruses Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma A recombinant vesicular stomatitis virus 756 bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that 757 restores fusion Specificity, cross-reactivity, and function of 761 antibodies elicited by Zika virus infection Identification of protective epitopes on ebola virus glycoprotein at the 765 single amino acid level by using recombinant vesicular stomatitis viruses Tailored tetravalent antibodies potently and specifically 769 activate Wnt/Frizzled pathways in cells, organoids and mice Human monoclonal antibody 773 combination against SARS coronavirus: synergy and coverage of escape mutants Structural insights into coronavirus entry An efficient method to make human 780 monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus Chimeric Viruses with Vesicular Stomatitis 785 Virus: Actions in the Brain Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Site-specific 791 glycan analysis of the SARS-CoV-2 spike Efficient recovery of infectious 794 vesicular stomatitis virus entirely from cDNA clones Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-802 SARS-CoV-2 infection of human small intestinal enterocytes Probable Pangolin Origin of SARS-CoV-2 Associated 809 with the COVID-19 Outbreak A pneumonia outbreak associated with a new coronavirus of probable bat 813 origin • Neutralization can be assessed by BSL2 and BSL3 high-throughput assays • SARS-CoV-2 and VSV-SARS-CoV-2-based neutralization assays correlate eTOC Blurb generate a replication-competent vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike and compare the neutralizing activity of antibodies with VSV-SARS-CoV-2 to fully infectious SARS-CoV-2.
    keywords: coronavirus; cov-2; sars; spike; vesicular; virus; vsv
       cache: cord-286390-ytgw3j4s.txt
  plain text: cord-286390-ytgw3j4s.txt

        item: #22 of 39
          id: cord-290243-m8yfugr0
      author: Kim, Kyung Ran
       title: Design, synthesis, and biological evaluation of novel iso-d-2′,3′-dideoxy-3′-fluorothianucleoside derivatives
        date: 2007-01-01
       words: 3422
      flesch: 45
     summary: NMR data were recorded on a Bruker AC200 and Varian Unity AS 500 spectrometer, using CDCl 3 , or CD 3 OD and chemical shifts were reported in parts per million (ppm) with reference to the respective residual solvent or deuteriated peaks (d H 3.30 and d C 49.0 for CD 3 OD, d H 7.26 and d C 77.0 for CDCl 3 ). This result implies that iso-2′,3′-dideoxy sugar templates might play a role of a sugar surrogate of nucleosides for the development of anti-RNA virus agent.
    keywords: mixture; mmol; nucleoside; reaction; solution
       cache: cord-290243-m8yfugr0.txt
  plain text: cord-290243-m8yfugr0.txt

        item: #23 of 39
          id: cord-291323-kbjyd5g3
      author: Kang, Yuan-Lin
       title: Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2
        date: 2020-08-25
       words: 5313
      flesch: 38
     summary: These inhibitors include Apilimod (19) , Vacuolin-1 (18), a series of 30 Vacuolin-related The membrane fusion proteins of viral pathogens as diverse in their replication strategies as coronaviruses and filoviruses depend, for their functional activity, on proteolytic processing during cell entry. Cell entry of SARS-CoV and SARS-CoV-2 depends on the protease TMPRSS2 in conjunction with ACE2 (34) (35) (36) (37) , and, when TMPRSS2 is present, the entry pathway becomes insensitive to cathepsin inhibition (34, 37, 38) .
    keywords: apilimod; cells; cov-2; endosomal; entry; infection; kinase; megfp; npc1; pikfyve; sars; virus; vsv; zebov
       cache: cord-291323-kbjyd5g3.txt
  plain text: cord-291323-kbjyd5g3.txt

        item: #24 of 39
          id: cord-292593-apdyaujt
      author: Coulter-Mackie, Marion
       title: In vivo and in vitro models of demyelinating diseases XII. Persistence and expression of corona JHM vims functions in RN2-2 Schwannoma cells during latency
        date: 1985-10-31
       words: 5842
      flesch: 51
     summary: To ascertain whether active translation was underway at 39.5C, polysomes from infected RN2 cells were isolated, fractionated and subjected to hybridization with JHMV-specific [ 32P]cDNA and autoradiography, as described in Materials and Methods. Cells were released from tissues by mincing and dispersal into phosphate-buffered saline, containing 22 mM glucose and 0.25% trypsin, employing agitation at 37°C for 15 min.
    keywords: cells; days; ifn; infected; infection; jhmv; latency; rn2; virus
       cache: cord-292593-apdyaujt.txt
  plain text: cord-292593-apdyaujt.txt

        item: #25 of 39
          id: cord-296187-nnv2e7gr
      author: Mulgaonkar, Nirmitee
       title: Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
        date: 2020-08-18
       words: 4966
      flesch: 50
     summary: key: cord-296187-nnv2e7gr authors: Mulgaonkar, Nirmitee; Wang, Haoqi; Mallawarachchi, Samavath; Fernando, Sandun; Martina, Byron; Ruzek, Daniel title: Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19 date: 2020-08-18 journal: bioRxiv DOI: 10.1101/2020.06.18.158196 sha: doc_id: 296187 cord_uid: nnv2e7gr The rapid geographic expansion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infectious agent of Coronavirus Disease 2019 (COVID-19) pandemic, poses an immediate need for potent drugs. VSV-G particles cells do not carry spike proteins and thus, no significant entry inhibition occurred, suggesting that entry inhibition is likely mediated through the spike protein.
    keywords: ace2; binding; cells; cov-2; fusion; imatinib; kinase; protein; rbd; receptor; sars; spike; vsv
       cache: cord-296187-nnv2e7gr.txt
  plain text: cord-296187-nnv2e7gr.txt

        item: #26 of 39
          id: cord-296399-vvbjulm9
      author: Brinkmann, Constantin
       title: The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells
        date: 2017-12-07
       words: 7023
      flesch: 38
     summary: These observations could indicate that VSV-G-mediated tetherin antagonism is not operative in VSV infected cells. Moreover, siRNAmediated knock-down of endogenous tetherin expression in HeLa cells reduced the amount of cell surface associated tetherin (Fig 3B) and increased viral titers roughly 10-fold as compared to cells transfected with scrambled siRNA or mock transfected cells (Fig 3C) .
    keywords: antagonism; cells; ebov; expression; fig; medium; protein; release; spread; tetherin; virus; vpu; vsv
       cache: cord-296399-vvbjulm9.txt
  plain text: cord-296399-vvbjulm9.txt

        item: #27 of 39
          id: cord-296466-hakaoo9i
      author: Mäkelä, Anna R.
       title: Baculovirus Display: A Multifunctional Technology for Gene Delivery and Eukaryotic Library Development
        date: 2006-09-22
       words: 7660
      flesch: 25
     summary: Cell surface display can be applied in library screening for studying ligand-receptor interactions and antigen recognition. In 1997, Granziero et al. (1997) aimed to develop a rapid method for generating baculovirus-based cDNA expression libraries for screening cell surface molecules, for which antibodies are available beforehand and whose expression pattern is restricted to particular cell types.
    keywords: antibodies; baculovirus; cells; display; envelope; et al; expression; fusion; gene; gp64; insect; membrane; proteins; surface; targeting; transduction; vectors; viral; vsv
       cache: cord-296466-hakaoo9i.txt
  plain text: cord-296466-hakaoo9i.txt

        item: #28 of 39
          id: cord-299281-5z1xminb
      author: None
       title: Oligomerization of a membrane protein correlates with its retention in the Golgi complex
        date: 1993-09-02
       words: 8182
      flesch: 47
     summary: We are currently constructing a series of Gml proteins with truncated cytoplasmic tails to determine if these proteins are correctly targeted and form oligomers. When the membrane-spanning domain of a protein which is efficiently delivered to the plasma membrane (VSV G protein) is replaced with m1, the resulting chimera (Gm1) is retained in the Golgi (Swift, A. M., and C. E. Machamer. 1991.
    keywords: cells; domain; fig; gml; golgi; membrane; min; oligomer; proteins; sds; trypsin; vsv
       cache: cord-299281-5z1xminb.txt
  plain text: cord-299281-5z1xminb.txt

        item: #29 of 39
          id: cord-316589-f1hq0xl5
      author: Nagalo, Bolni Marius
       title: Oncolytic Virus With Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
        date: 2020-08-19
       words: 1728
      flesch: 17
     summary: Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNbeta-NIS A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma Pre-clinical development of a vaccine against Lassa fever A VSV-based Zika virus vaccine protects mice from lethal challenge Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSVbased vaccine The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein Vesiculovirus neutralization by natural IgM and complement Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands rVSV(M Delta
    keywords: cd46; measles; oncolytic; stomatitis; virus; vsv
       cache: cord-316589-f1hq0xl5.txt
  plain text: cord-316589-f1hq0xl5.txt

        item: #30 of 39
          id: cord-318587-ewvnkdr2
      author: Steeds, Kimberley
       title: Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies
        date: 2020-08-31
       words: 4989
      flesch: 35
     summary: Pseudotyped virus neutralisation assay raw data were normalised as percentage (%) infection relative to mean values for pseudotyped virus only controls (equivalent to 100% infection), then IC 50 of pseudotyped virus neutralisation were estimated by model of nonlinear regression fit with settings for log (inhibitor) vs. normalised response curves using GraphPad Prism v5 (San Diego, California (CA), USA). A number of EBOV GP pseudotyped virus neutralisation assays have been developed to investigate immune responses to EBOV infection and vaccination [16] [17] [18] , as well as for evaluation of monoclonal antibody (mAb) therapies [19]
    keywords: assay; cells; ebola; ebov; neutralisation; plasma; pseudotyped; virus; viruses; vsv
       cache: cord-318587-ewvnkdr2.txt
  plain text: cord-318587-ewvnkdr2.txt

        item: #31 of 39
          id: cord-318686-we6pveus
      author: Ehlen, Lukas
       title: Epithelial cell lines of the cotton rat (Sigmodon hispidus) are highly susceptible in vitro models to zoonotic Bunya-, Rhabdo-, and Flaviviruses
        date: 2016-05-04
       words: 5618
      flesch: 46
     summary: For virus infection experiments, the medium was removed and cells were inoculated with virus diluted in Optipro serum-free medium (Life Technologies) for 1 h at 37°C. However, in contrast to experimental animals, cell lines are a less laborious model system, less expensive, and can be used in large-scale viral experiments such as in virus isolation trials without the ethical considerations that are involved in animal experiments.
    keywords: cells; cotton; epithelial; hispidus; infection; lines; log; novel; rats; viral; virus; viruses
       cache: cord-318686-we6pveus.txt
  plain text: cord-318686-we6pveus.txt

        item: #32 of 39
          id: cord-324674-yd7idp90
      author: Zhang, Chengfei
       title: IFN-stimulated P2Y(13) protects mice from viral infection by suppressing the cAMP/EPAC1 signaling pathway
        date: 2018-08-22
       words: 6107
      flesch: 52
     summary: P2 receptors can be further divided into P2Y receptors (P2YRs) and P2X receptors (P2XRs) based on their structures and distinct signaltransduction mechanisms. Furthermore, the protein expression of vesicular stomatitis virus glycoprotein (VSV-G) was significantly increased in P2Y 13 -deficient PEMs and overexpression of P2Y 13 in HeLa cells significantly repressed VSV replication ( Figure 3I ; Supplementary Figure 1 IFN signal pathway increases P2Y 13 expression.
    keywords: adp; cells; epac1; expression; figure; ifn; infection; p2y; rna; vsv
       cache: cord-324674-yd7idp90.txt
  plain text: cord-324674-yd7idp90.txt

        item: #33 of 39
          id: cord-326013-5i35zdmv
      author: Carpinteiro, Alexander
       title: Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells
        date: 2020-10-29
       words: 3116
      flesch: 37
     summary: The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model Acid sphingomyelinase/ceramide system mediates effects of antidepressant drugs Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide Emerging mechanisms of drug-induced phospholipidosis Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection SARS-CoV-2 receptor ACE2 is an Interferonstimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues Increase of heart rate and QTc by Amitripytline, but not by Venlafaxine, is correleated to serum concentration Association between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with coronavirus disease 2019: a multicenter retrospective observational study The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 Quantitative modeling of selective lysosomal targeting for drug design Distribution and fate of C14-amitriptyline in mice and rats Postmortem release of amitriptyline from the lungs; a mechanism of postmortem drug redistribution Postmortem distribution of tramadol, amitriptyline, and their metabolites in a suicidal overdose Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2 Ceramide is upregulated and associated with mortality in patients with chronic heart failure The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases A Vesicular Stomatitis Virus replicon-based bioassay for the rapid and sensitive determination of multispecies type I Interferon Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization Here we report that either pharmacological inhibition of acid sphingomyelinase with amitriptyline, imipramine, fluoxetine, sertraline, escitalopram, or maprotiline, or genetic downregulation of the enzyme prevents infection of cultured cells or freshy isolated human nasal epithelial cells with SARS-CoV-2 or pseudoviral pp-VSV-SARS-CoV-2 particles expressing spike, a bona fide system mimicking SARS-CoV-2 infection.
    keywords: acid; amitriptyline; cells; ceramide; cov-2; infection; sars; sphingomyelinase
       cache: cord-326013-5i35zdmv.txt
  plain text: cord-326013-5i35zdmv.txt

        item: #34 of 39
          id: cord-327199-ggomuomb
      author: Moerdyk-Schauwecker, Megan
       title: Cellular Proteins Associated with the Interior and Exterior of Vesicular Stomatitis Virus Virions
        date: 2014-08-08
       words: 6429
      flesch: 35
     summary: mature and extracellular enveloped virions Protein composition of the vaccinia virus mature virion Identification of proteins associated with murine gammaherpesvirus 68 virions Proteomic analysis of pathogenic and attenuated alcelaphine herpesvirus 1 Proteins of purified Epstein-Barr virus Identification of proteins associated with murine cytomegalovirus virions Comprehensive characterization of extracellular herpes simplex virus type 1 virions Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome Virion proteins of Kaposi's sarcomaassociated herpesvirus Proteomic characterization of pseudorabies virus extracellular virions Cellular proteins in influenza virus particles Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3 Proteomic analysis of purified coronavirus infectious bronchitis virus particles Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages Proteomic analysis of human immunodeficiency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteins Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations Distinct host cell proteins incorporated by SIV replicating in CD4+ T cells from natural disease resistant versus non-natural disease susceptible hosts Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly Proteomic analysis of purified Newcastle disease virus particles Proteomics of the Autographa californica nucleopolyhedrovirus budded virions Correlation between structure, protein composition, morphogenesis and cytopathology of Glossina pallidipes salivary gland hypertrophy virus Profiling of cellular proteins in porcine reproductive and respiratory syndrome virus virions by proteomics analysis Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach A single amino acid change in the L-polymerase protein of vesicular stomatitis virus completely abolishes viral mRNA cap methylation Recombinant vesicular stomatitis viruses from DNA The lipidomes of vesicular stomatitis virus, semliki forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry Specific interactions of vesicular stomatitis virus L and NS proteins with heterologous genome ribonucleoprotein template lead to mRNA synthesis in vitro Systematic characterization of nuclear proteome during apoptosis: a quantitative proteomic study by differential extraction and stable isotope labeling Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search Code developments to improve the efficiency of automated MS/MS spectra interpretation Mining genomes: correlating tandem mass spectra of modified and unmodified peptides to sequences in nucleotide databases Future prospects for the analysis of complex biological systems using micro-column liquid chromatography-electrospray tandem mass spectrometry Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists Biophysical studies of vesicular stomatitis virus Structural domains of vesicular stomatitis virus. Here we aimed to determine the localization of host proteins within the VSV virions by analyzing: i) whole VSV virions; and ii) whole VSV virions treated with Proteinase K to remove all proteins outside the viral envelope.
    keywords: analysis; budding; cell; host; human; prok; proteins; rnp; stomatitis; type; virions; virus; viruses; vsv
       cache: cord-327199-ggomuomb.txt
  plain text: cord-327199-ggomuomb.txt

        item: #35 of 39
          id: cord-339854-scb7pz87
      author: Overend, Christopher
       title: The synthetic futures of vesicular stomatitis virus
        date: 2012-07-11
       words: 1090
      flesch: 36
     summary: Trends in Biotechnology October 2012, Vol. 30, No. 10 Synthetic viruses: a new opportunity to understand and prevent viral disease Vesicular stomatitis virus: re-inventing the bullet Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4(+) cells are required at the time of challenge for optimal protection Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain SARS vaccine based on a replicationdefective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector Writing DNA with GenoCAD (TM) Vesicular stomatitis virus (VSV) is one of the most promising viruses for engineering vaccines and oncolytic therapies [2] .
    keywords: challenge; vaccine; virus; vsv
       cache: cord-339854-scb7pz87.txt
  plain text: cord-339854-scb7pz87.txt

        item: #36 of 39
          id: cord-345299-4k7qymqd
      author: Xiong, Hua-Long
       title: Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro
        date: 2020-06-05
       words: 1479
      flesch: 38
     summary: Re-purposing of approved drugs may be a faster way to find treatment for COVID-19. In this study, the anti-SARS-Cov-2 potentiality of 1403 FDA approved drugs were quantitatively evaluated by the pseudovirus-based assay.
    keywords: cov-2; drugs; infection; sars
       cache: cord-345299-4k7qymqd.txt
  plain text: cord-345299-4k7qymqd.txt

        item: #37 of 39
          id: cord-346554-a98pjtxs
      author: Uddin, Md Bashir
       title: Inhibitory effects of bee venom and its components against viruses in vitro and in vivo
        date: 2016-11-26
       words: 7918
      flesch: 48
     summary: BV or MLT antiviral activity was tested in HeLa cells with H3-GFP and EV-71 viruses using standard antiviral activity assays. Additionally, BV or MLT antiviral activity for EV-71 was determined by evaluating 50% tissue culture infective dose (TCID 50 ) and analysis of mRNA expression levels of the EV-71 VP1 gene.
    keywords: activity; antiviral; cells; ev-71; fig; gfp; mlt; pr8; virus; viruses; vsv
       cache: cord-346554-a98pjtxs.txt
  plain text: cord-346554-a98pjtxs.txt

        item: #38 of 39
          id: cord-346777-zmmnn9b2
      author: Lester, Sandra
       title: Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies
        date: 2019-09-11
       words: 5378
      flesch: 38
     summary: The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents Serological assays for emerging coronaviruses: challenges and pitfalls Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses Host cell entry of middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies Pseudotyped lentiviral vectors: one vector, many guises Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt Lack of MERS coronavirus neutralizing antibodies in humans, eastern Province, Saudi Arabia Evaluation of candidate vaccine approaches for MERS-CoV Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution Receptor variation and susceptibility to middle East respiratory syndrome coronavirus infection Proteolytic processing of middle East respiratory syndrome coronavirus spikes expands virus tropism Adaptive evolution of MERS-CoV to species variation in DPP4 Inability of rat DPP4 to allow MERS-CoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein Development of a neutralization assay for Nipah virus using pseudotype particles The production and development of H7 influenza virus pseudotypes for the study of humoral responses against avian viruses Comparative serological assays for the study of H5 and H7 avian influenza viruses Safe pseudovirusbased assay for neutralization antibodies against influenza A(H7N9) virus Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26 Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus Reverse genetics with a full-length infectious cDNA of the middle East respiratory syndrome coronavirus Transgene expression in the genome of middle East respiratory syndrome coronavirus based on a novel reverse genetics system utilizing red-mediated recombination cloning Cross-Reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests The authors wish to acknowledge financial support from CDC LASSI 2016. Efficient packaging of MERS-CoV S on the surface of the VSV pseudoparticles and the ability of the pseudoparticles to enter target cells through receptor binding were confirmed by comparing the titrated inoculation of Vero and BHK-21 cells of negative control VSV pseudoparticles containing no viral glycoproteins on their surface (VSV-EV) with that for VSV pseudotyped with MERS-CoV-S proteins, designated VSV-MERS-S (Fig.
    keywords: antibodies; assay; coronavirus; cov; human; mers; neutralization; protein; pseudoparticles; serum; vsv
       cache: cord-346777-zmmnn9b2.txt
  plain text: cord-346777-zmmnn9b2.txt

        item: #39 of 39
          id: cord-351881-qea4b0i5
      author: Eck, Melanie
       title: Virus replicon particles expressing porcine reproductive and respiratory syndrome virus proteins elicit immune priming but do not confer protection from viremia in pigs
        date: 2016-02-19
       words: 6306
      flesch: 44
     summary: In order to address the question whether PRRSV structural proteins are immunogenic at all when expressed by VSV VRP in pigs, a vector expressing PRRSV N protein was included in one vaccination trial. For the detection of PRRSV proteins, monoclonal antibody (mAb) 13E2 directed against PRRSV N, and mAb VII2D directed against amino acids 73-84 of PRRSV GP3 were kindly provided by Hans Nauwynck (University Ghent, Belgium).
    keywords: challenge; day; gp3; gp4; gp5; infection; pigs; porcine; proteins; prrsv; syndrome; virus; vrp; vsv
       cache: cord-351881-qea4b0i5.txt
  plain text: cord-351881-qea4b0i5.txt

